medigraphic.com
ISSN 2078-7170 (Electronic)

2012, Number 2

<< Back Next >>

CorSalud 2012; 4 (2)

Complexity of coronary lesions in diabetic patients

Pacheco GG, Obregón SÁG, Aroche AR, Conde CH, Hernández NM, Gandarilla SJC

Language: Spanish
References: 15
Page: 92-96
PDF size: 167.16 Kb.


ABSTRACT

Introduction and Objectives: Coronary artery disease in diabetic patients is presented in a very aggressive form with excessive progression of atherosclerosis and increased risk of stent restenosis or thrombosis in percutaneous coronary intervention. The objective of this research was to determine the relationship between diabetes mellitus and certain characteristics of coronary lesions and their relation with restenosis, thrombosis and development of new lesions after percutaneous procedure. Method: A retrospective-descriptive study was performed. Out of the 1,464 patients revascularized at the Medical and Surgical Research Center in Havana, Cuba, between August 1997 and February 2009, 270 diabetic patients were selected. Results: Diabetes mellitus was a risk factor for the following lesions: circumflex (OR*=1.48); ostium aorto-coronary (OR=3.58), left anterior descending (OR=2.41) and circumflex (OR=4.89), and trunk lesions extending into the left anterior descending artery (OR=9.79). Diabetics were more likely to develop complex lesions type B2 and C (OR=1.36), for curves higher than 90º (OR=3.03), with previous curves higher of 90 °(OR=6.13), injuries of more than 20 mm (OR=2.0), in branches (OR=1.69) and injuries due to absence of coronary flow (OR=4.15). They were also characterized by having smaller arteries of 3 mm (OR=1.32) and increased risk of developing new lesions (OR=2.11), restenosis (OR=2.11) and throm-bosis (OR=3.06) of stent. Conclusions: Diabetes mellitus was a risk factor for the development of complex coronary lesions with a high risk of further lesions, restenosis and stent thrombosis.


REFERENCES

  1. Lloyd-Jones D, Adams R, Carnethon M, De Si-mone G. Heart Disease and Stroke Statistics_2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3): e21-e181.

  2. Morgan KP, Kapur A, Beatt KJ. Anatomy of coronary disease in diabetic patients: an ex-planation for poorer outcomes after percutaneous coronary intervention and potential target for intervention. Heart. 2004;90(7):732-8.

  3. Mosseri M, Nahir M, Rozenman Y, Lotan C, Admon D, Raz I, et al. Diffuse narrowing of coronary arteries in diabetic patients: the earliest phase of coronary artery disease. Cardiology. 1998;89(2): 103-10.

  4. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA. 2005;293 (12):1501-8.

  5. Palomo Villada JA, Bernal E, Santiago J, Abundes Velasco A, Montoya Silvestre A, Flores Flores J, et al. Reestenosis clínica en pacientes diabéticos con implante de stents liberadores de fármaco en lesiones de novo. Arch Cardiol Mex. 2007;77(2): 110-9.

  6. Jiménez-Quevedo P, Sabaté M. Revascularización coronaria en diabéticos: evidencias, indicaciones y complicaciones. Rev Esp Cardiol. 2007;7(Supl E): 41-8.

  7. Daemen J, Kuck KH, Macaya C, LeGrand V, Vrolix M, Carrie D, et al; ARTS-II Investigators. Multi-vessel coronary revascularization in patients with and without diabetes mellitus: 3-year followup of the ARTS-II (Arterial Revascularization Therapies Study – Part II) trial. J Am Coll Cardiol. 2008; 52(24):1957-67.

  8. Philpott AC, Southern DA, Clement FM, Galbraith A, Trabulsi M, Knudtson ML, et al; the APPROACH Investigators. Longterm outcomes of patients receiving drug-eluting stents. CMAJ 2009;180(2): 167-74.

  9. ClinicalTrials.gov. Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals With Diabetes (FREEDOM) [Internet]. USA: NIH; 2009 [8 Jul 2009). Disponible en: http://www.clinicaltrials.gov/ct/show/NCT00086450

  10. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scien-tific statement from the American Heart Association and the American Diabetes Association. Circula-tion. 2007;115:114-26.

  11. Ong AT, Serruys PW, Mohr FW, Morice MC, Kappetein AP, Holmes DR, et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. Am Heart J. 2006;151(6):1194-204.

  12. Caixeta, A, León MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, et al. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol. 2009;54(10):894-902.

  13. Bainey KR, Norris CM, Graham MM, Ghali WA, Knudtson ML, Welsh RC; APPROACH investi-gators. Clinical in-stent restenosis with bare metal stents: is it truly a benign phenomenon? Int J Cardiol. 2008;128(3):378-82.

  14. Spinler SA. Percutaneous coronary intervention; assessing coronary vascular risk associated with bare-metal and drug-eluting stents. Am J Manag Care. 2009;15(2 Suppl):S42-7.

  15. Dixon SR, Grines CL, O’Neill WW. The Year in Interventional Cardiology. J Am Coll Cardiol. 2008; 51:2355-69.




2020     |     www.medigraphic.com